Evidence map›Paper›PMID 31596872›Full record

ArticlePloS one2019

Clinical significance and prognostic role of hypoxia-induced microRNA 382 in gastric adenocarcinoma.

An Na Seo, Yukdong Jung, Hyeonha Jang, Eunhye Lee, Han-Ik Bae, Taekwon Son, Ohkyung Kwon, Ho Young Chung, Wansik Yu, You Mie Lee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. The Impact ofBiomedicines · 2025
    Article
  2. Article
  3. Review
  4. FOXD2 regulations IQGAP3 mediated CaThe Kaohsiung journal of medical sciences · 2023
    Article
  5. Review
  6. Review
  7. Reduced circulating exosomal miR-382 predicts unfavorable outcome in non-small cell lung cancer.International journal of clinical and experimental pathology · 2021
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

An Na SeoDepartment of Pathology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Yukdong JungBK21 Plus KNU Multi-Omics Based Creative Drug Research Team, College of Pharmacy, Kyungpook National University, Daegu, South Korea.
Hyeonha JangBK21 Plus KNU Multi-Omics Based Creative Drug Research Team, College of Pharmacy, Kyungpook National University, Daegu, South Korea.
Eunhye LeeDepartment of Pathology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Han-Ik BaeDepartment of Pathology, School of Medicine, Kyungpook National University, Daegu, South Korea.
Taekwon SonResearch Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea.ORCID 0000-0002-6096-2231
Ohkyung KwonDepartment of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
Ho Young ChungDepartment of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea.
Wansik YuDepartment of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea.
You Mie LeeBK21 Plus KNU Multi-Omics Based Creative Drug Research Team, College of Pharmacy, Kyungpook National University, Daegu, South Korea.ORCID 0000-0002-5756-7169
Kyungpook National University Hospital · KRKyungpook National University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia and angiogenesis are critical components in the progression of solid cancer, including gastric cancers (GCs). miR-382 has been identified as a hypoxia-induced miR (hypoxamiR), but the clinical significance in GCs has not been identified yet. To explore the clinical and prognostic importance of miR-382 in GCs, the surgical specimens of 398 patients with GCs in KNU hospital in Korea, the total of 183 patients was randomly selected using simple sampling methods and big data with 446 GCs and 45 normal tissues from the data portal (https://portal.gdc.cancer.gov/) were analysed. Expression of miR-382 as well as miR-210, as a positive control hypoxamiR by qRT-PCR in histologically malignant region of GCs showed significantly positive correlation (R = 0.516, p<0.001). High miR-210 and miR-382 expression was significantly correlated with unfavorable prognosis including advanced GCs (AGC), higher T category, N category, pathologic TNM stage, lymphovascular invasion, venous invasion, and perinueral invasion, respectively (all p<0.05). In univariate analysis, high miR-210 expression was significantly associated with worse overall survival (OS) (p = 0.036) but not high miR-382. In paired 60 gastric normal and cancer tissues, miR-382 expression in cancer tissues was significantly higher than normal counterpart (p = 0.003), but not miR-210 expression. However, by increasing the patient number from the big data analysis, miR-210 as well as miR-382 expression in tumor tissues was significantly higher than the normal tissues. Our results suggest that miR-382, as novel hypoxamiR, can be a prognostic marker for advanced GCs and might be correlated with metastatic potential. miR-382 might play important roles in the aggressiveness, progression and prognosis of GCs. In addition, miR-382 give a predictive marker for progression of GCs compared to the normal or preneoplastic lesion.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overBiomarkers, TumorCell HypoxiaFemaleHumansMaleMicroRNAsMiddle AgedSensitivity and SpecificityStomach NeoplasmsSurvival AnalysisBiomarkers, TumorMicroRNAsMIRN382 microRNA, human

Identifiers

PMID31596872
PMCPMC6785122
OpenAlexW2980270807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.